Eptifibatide (CAS 188627-80-7) is a high-purity, pharmaceutical-grade antiplatelet agent synthesized via advanced peptide synthesis technology, fully complying with USP and EP quality standards. Its molecular structure is engineered to selectively block glycoprotein IIb/IIIa receptors on platelet surfaces, preventing platelet aggregation and thrombus formation with high specificity. Produced with strict control over peptide chain purity (total impurities ≤0.08%) and biological activity, each batch undergoes rigorous in vitro validation, making it a reliable raw material for cardiovascular drug formulation.
This potent antiplatelet peptide stands out for its rapid onset of action and reversible binding mechanism, ideal for acute coronary syndrome (ACS) management and percutaneous coronary intervention (PCI) support. Unlike oral antiplatelet drugs, it exerts immediate effects to reduce ischemic events, while its reversible properties minimize bleeding risks—a critical advantage for clinical applications. Its stable peptide structure also supports formulation into injectable solutions, catering to emergency cardiovascular care needs.
Eptifibatide (CAS 188627-80-7) caters to professional users including pharmaceutical manufacturers developing anti-thrombotic medications, research institutions exploring platelet receptor pharmacology, and biotech firms advancing cardiovascular therapies. Its proven clinical efficacy, pharmaceutical-grade purity, and targeted mechanism make it a top choice for buyers prioritizing safety and therapeutic performance. Whether for large-scale commercial production or preclinical research, this antiplatelet agent meets the stringent demands of the global cardiovascular pharmaceutical sector.
